Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q2 2023 · 10-Q
Revenue$3.33M$3.33M−11.0% vs Q2 2022 Net Income-$1.02M-$1.02MN/M vs Q2 2022 EPS Diluted-$0.33-$0.33N/M vs Q2 2022 Gross Profit$1,536,000+23.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,830,000N/M Free Cash Flowderived-$1,855,000N/M Margins · derivedGross margin46.1%+13.0 pt vs Q2 2022
Operating margin-21.9%+3.8 pt vs Q2 2022
Net margin-30.5%−27.9 pt vs Q2 2022
ended Sep 30, 2022 · filed Nov 14, 2022 · 45 d after period end